TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30541093
Drug: Whole-grain wheat
Normalized name: rice (whole grain) allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-grain wheat (WGW) 98 g/d
Study: 30541093
Drug: Refined wheat
Normalized name: WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Refined wheat (RW) 98 g/d
Study: 24484688
Drug: Subcutaneous hydration
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous hydration (up to 1.5 l/day for 72 hours)
Study: 24484688
Drug: Intravenous hydration
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hydration (up to 1.5 l/day for 72 hours)
Study: 24484688
Drug: Subcutaneous hydration
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous hydration
Study: 22233189
Drug: Very low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Very low-dose naltrexone (VLNTX) 0.125 or 0.25 mg/day
Study: 22233189
Drug: Very low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Very low-dose naltrexone (VLNTX) + clonidine (0.1-0.2 mg q6h)
Study: 22233189
Drug: Clonidine (0.1-0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.1-0.2 mg q6h)
Study: 21054829
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (counselling on daily physical activity, physical fitness training, sports advice)
Study: 21054829
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment; current policy)
Study: 17391155
Drug: 0.5% aminophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% aminophylline cream applied to the waist twice a day
Study: 17391155
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (control) applied to the waist
Study: 15766477
Drug: Kaiku's Benecol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kaiku's Benecol containing 2 g/bottle of plant stanol esters
Study: 12018956
Drug: Phenobarbitone (prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbitone (prophylactic treatment)
Study: 9831406
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (bismuth subnitrate 3 x 375 mg for 4 weeks + tetracycline 3 x 500 mg + metronidazole 3 x 250 mg daily for 2 weeks)
Study: 9831406
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (amoxicillin 2 x 1000 mg + omeprazole 2 x 20 mg daily for 2 weeks)
Study: 25265768
Drug: Neostigmine 2.5
Normalized name: neostigmine 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 2.5 mg and atropine 1.2 mg
Study: 3190971
Drug: No drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drugs to facilitate antagonism of blockade (Control)
Study: 15480592
Drug: Preparation period
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation period of motor acts
Study: 11247549
Drug: DOTS with
Normalized name: D3 Dots
Approvals — FDA: no, EMA: no, PMDA: no
Description: DOTS with direct observation of treatment by health workers
Study: 11247549
Drug: DOTS with
Normalized name: D3 Dots
Approvals — FDA: no, EMA: no, PMDA: no
Description: DOTS with direct observation of treatment by family members
Study: 7876505
Drug: Oral mesalamine
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral mesalamine (Asacol) 3.2 g/day
Study: 3284724
Drug: Penicillin and
Normalized name: Benzathine benzylpenicillin and procaine benzylpenicillin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penicillin and streptomycin (penicillin, 2 ml, IU, intramuscularly, three times daily for six days; streptomycin, 0.5 gm, intramuscularly, two times daily for four days)
Study: 31180763
Drug: Home-based exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based exercise programme with monthly reinforcement sessions
Study: 25927495
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavioral therapy (CBT) program
Study: 19812871
Drug: Tramiprosate 100
Normalized name: TRAMIPROSATE
DrugBank: Tramiprosate (DB06527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramiprosate 100 mg
Study: 19812871
Drug: Tramiprosate 150
Normalized name: TRAMIPROSATE
DrugBank: Tramiprosate (DB06527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramiprosate 150 mg
Study: 14529954
Drug: 325 mg
Normalized name: lysine 325 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 325 mg lamotrigine (LTG) as a single dose
Study: 14529954
Drug: bi-hourly graded
Normalized name: bis-ethoxydiglycol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: bi-hourly graded cumulative dose of lamotrigine (LTG)
Study: 8126258
Drug: Diltiazem 60
Normalized name: DILTIAZEM 60MG 12HR CAP,SA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 60 mg
Study: 10716041
Drug: Tolbutamide 500
Normalized name: tolbutamide 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolbutamide 500 mg
Study: 7750592
Drug: Ethanol (1
Normalized name: ALCOHOL 95 mL in 100 mL TOPICAL SOLUTION [95% Ethanol (190 Proof)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (1 mL/kg 95% ethanol)
Study: 2020905
Drug: Anticoagulant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant treatment (AC group)
Study: 2020905
Drug: No anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anticoagulant treatment (O group)
Study: 7039927
Drug: Indomethacin (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (0.2 mg/kg for 2 doses, orally, 24 hours apart)
Study: 29749112
Drug: Technology-enhanced writing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Technology-enhanced writing therapy (12 hours)
Study: 29749112
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (waitlist, no therapy for 6 weeks)
Study: 26892695
Drug: 200μg sublingual
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200μg sublingual misoprostol
Study: 26892695
Drug: 400μg sublingual
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400μg sublingual misoprostol
Study: 20155327
Drug: Intensified treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified treatment (n = 255)
Study: 20155327
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment according to Dutch guidelines (n = 243)
Study: 18089478
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (fix combination of 4/1.25 mg perindopril/indapamide)
Study: 10338459
Drug: valsartan 160
Normalized name: valsartan 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: valsartan 160 mg BID
Study: 10338459
Drug: valsartan 80
Normalized name: valsartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: valsartan 80 mg BID
Study: 1658183
Drug: Lisinopril 10
Normalized name: lisinopril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 10 mg daily
Study: 1658183
Drug: Lisinopril and
Normalized name: lisinopril and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril and physical training
Study: 28562099
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone gel 1% (androgel) before Controlled Ovarian Stimulation (COS)
Study: 28562099
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no testosterone gel)
Study: 26787797
Drug: Dexketoprofen/tramadol 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexketoprofen/tramadol 25 mg/75 mg
Study: 25412338
Drug: Glutamine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine (15 g bd) + sitagliptin (100 mg/d)
Study: 25412338
Drug: Glutamine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine (15 g bd) + placebo
Study: 17722962
Drug: Tacrolimus once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus once-daily (OD)
Study: 17722962
Drug: Standard tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard tacrolimus (twice daily)
Study: 16221103
Drug: Intravenous cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cyclophosphamide (IVC) 0.75-1 g/m² monthly for 6 months
Study: 20169461
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 2 g/day for 6 months
Study: 21917733
Drug: Intravenous cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cyclophosphamide (IVC)
Study: 2990196
Drug: 30 ml
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml of liquid antacid (aluminum and magnesium hydroxide)
Study: 18241718
Drug: Palatal implants
Normalized name: malate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palatal implants
Study: 30903117
Drug: Palatal implants
Normalized name: malate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palatal implants or mini-screws
Study: 24151591
Drug: Test product
Normalized name: Patch test product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test product (cyclobenzaprine tablet)
Study: 24151591
Drug: Reference product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference product (cyclobenzaprine tablet)
Study: 11033132
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C (0.2 mg/mL for 2 minutes) with releasable sutures (Group 1)
Study: 7713197
Drug: MDI containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDI containing lecithin NF (MDI-L)
Study: 3453431
Drug: Nicergoline (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicergoline (30 mg twice a day) for 6 months (double-blind for PICD patients)
Study: 3453431
Drug: Nicergoline (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicergoline (30 mg twice a day) for at least 6 months (open design for PAD patients)
Study: 24825805
Drug: Intramuscular meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular meperidine injection administered 30 minutes before the biopsy
Study: 24825805
Drug: Periprostatic nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periprostatic nerve block (PNB) by injection 10 minutes prior to the prostate biopsy
Study: 16623075
Drug: Irbesartan/HCTZ 150/12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan/HCTZ 150/12.5 mg (8 weeks)
Study: 16623075
Drug: Irbesartan/HCTZ 300/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan/HCTZ 300/25 mg (8 weeks)
Study: 18681815
Drug: Irbesartan/HCTZ (overall
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan/HCTZ (overall treatment)
Study: 14514935
Drug: Self-management advice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-management advice from the pharmacist with weekly telephone follow up for 3 months
Study: 6536506
Drug: Postoperative continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative continuous epidural morphine (group C)
Study: 6536506
Drug: Oral phenoxybenzamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral phenoxybenzamine 10 mg (group D)
Study: 6536506
Drug: Postoperative mild
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative mild analgesics (group B)
Study: 30272094
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of MI and Omega-3 supplementation
Study: 17974883
Drug: Lyophilized bone
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyophilized bone chips with platelet gel (Group A)
Study: 17974883
Drug: Lyophilized bone
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyophilized bone chips with platelet gel and bone marrow stromal cells (Group B)
Study: 17974883
Drug: Lyophilized bone
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyophilized bone chips without gel (Group C)
Study: 12581547
Drug: Ciprofloxacin QD
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin QD 500 mg once daily for 3 days
Study: 12581547
Drug: Ciprofloxacin BID
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin BID 250 mg twice daily for 3 days
Study: 8665884
Drug: Bupivacaine 5
Normalized name: Sure-Amp BUPivacaine 5 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 5 mL
Study: 8665884
Drug: Bupivacaine 5
Normalized name: Sure-Amp BUPivacaine 5 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 5 mL plus Thiomucase 10 U mL‐1
Study: 8665884
Drug: Bupivacaine 9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 9 mL
Study: 8665884
Drug: Bupivacaine 9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 9 mL plus Thiomucase 10 U mL‐1
Study: 897173
Drug: Simethicone preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simethicone preparation
Study: 897173
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no simethicone preparation)
Study: 2766870
Drug: Perioperative antibiotic
Normalized name: ENSURE SURGERY PERIOPERATIVE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative antibiotic prophylaxis
Study: 30506144
Drug: Cinacalcet (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinacalcet (starting dose ≤ 0.20 mg/kg)
Study: 28456603
Drug: Lidocaine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (2 mg kg−1) IV over 1 minute
Study: 25056999
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (1 hour)
Study: 21315207
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg RB006
Study: 21315207
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin or low molecular heparin
Study: 16875447
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (identical treatment from a dummy cluster)
Study: 9410047
Drug: Dirithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dirithromycin (500 mg/day over 5 days)
Study: 9410047
Drug: Diacetylmidecamycin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diacetylmidecamycin (600 mg, twice daily over 7 days)
Study: 9536227
Drug: Calcipotriol ointment
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol ointment (50 micrograms/g) applied twice daily
Study: 4047707
Drug: Acetaminophen plus
Normalized name: acetaminophen / hydrocodone Oral Capsule [Ceta Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen plus codeine, 300 mg plus 30 mg
Study: 30799926
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (ITT and CC populations)
Study: 27423320
Drug: Intervention participants
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention participants who kept coach visits, attended group sessions, and used patches
Study: 24685561
Drug: 10-mg cocaine
Normalized name: cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-mg cocaine units
Study: 24685561
Drug: 0-mg cocaine
Normalized name: cocaine 0.1 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0-mg cocaine units
Study: 22066530
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy (20 mg of rabeprazole, 1 g of amoxicillin, and 500 mg of clarithromycin, twice daily for 7 days)
Study: 22066530
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy (5-day dual therapy: 20 mg of rabeprazole and 1 g of amoxicillin, twice daily, followed by 5-day triple therapy: 20 mg of rabeprazole, 500 mg of clarithromycin, and 500 mg of metronidazole, twice daily)
Study: 9255221
Drug: Insulin-like growth
Normalized name: Insulin-like growth factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-like growth factor I (IGF-I)
Study: 12127431
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg lamivudine daily for 4 weeks
Study: 12127431
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg lamivudine daily for 4 weeks
Study: 12127431
Drug: Previous lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Previous lamivudine treatment
Study: 12127431
Drug: Naive to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naive to lamivudine treatment
Study: 10198369
Drug: Subcutaneous IGF-I,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous IGF-I, 50 microgram/kg/day
Study: 7786592
Drug: platinum-based combination
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: platinum-based combination chemotherapy with or without doxorubicin (DX)
Study: 395854
Drug: Bupivacaine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (mean dose 130 mg)
Study: 395854
Drug: Pethidine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pethidine (mean dose 183.3 mg)
Study: 26001561
Drug: Monthly oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly oral ibandronate 100 mg
Study: 26001561
Drug: Monthly intravenous
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly intravenous ibandronate 1 mg
Study: 24113041
Drug: Simvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (40 mg/d) plus Policosanol (20 mg/d)
Study: 24113041
Drug: Simvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (40 mg/d) plus Placebo (20 mg/d)
Study: 17873142
Drug: Oral nicorandil
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nicorandil (15 mg/d) - Group A
Study: 10216812
Drug: Diltiazem (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (60 mg single dose)
Study: 10216812
Drug: Diltiazem (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (60 mg repeated doses three times a day for six days and 60 mg on the seventh day)
Study: 7598923
Drug: Droperidol 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 0.5 mg with morphine
Study: 7598923
Drug: Droperidol 1
Normalized name: droperidol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 1 mg with morphine
Study: 7352669
Drug: Midazolam maleate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam maleate, 10 mg (95% confidence limits: 9-12 mg)
Study: 7352669
Drug: Sodium thiopental,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium thiopental, 200 mg
Study: 22468985
Drug: Multimodal, nondrug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal, nondrug therapy (motor stimulation, activities of daily living, cognitive stimulation) for 6 months, 2 hours, 6 days a week
Study: 18513418
Drug: Statistical methods
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statistical methods for evaluating treatment effect from an RCT with a recurrent outcome
Study: 12869856
Drug: Cimetidine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (50 mg/hr) for 48 hours after aminophylline infusion
Study: 10500017
Drug: Tomato oleoresin
Normalized name: Tomato
DrugBank: Tomato (DB10573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomato oleoresin (70-75 mg lycopene)
Study: 10500017
Drug: Lycopene beadlets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lycopene beadlets (70-75 mg lycopene)
Study: 7570895
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of edrophonium and 3,4-diaminopyridine
Study: 1721516
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline prepared in hydroxyethylstarch solution (HS-HES, n = 15)
Study: 1721516
Drug: 6% HES
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% HES 200/0.5 solution (6% HES; n = 15)
Study: 15337874
Drug: Heparin administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin administration
Study: 31775669
Drug: Progesterone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone (200 mg) plus pessary
Study: 31775669
Drug: Progesterone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone (200 mg) alone
Study: 18950837
Drug: Thalidomide 300
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide 300 mg daily for 24 months
Study: 16714251
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT), given orally.
Study: 11725694
Drug: DION (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: DION (300 mg androstenedione, 150 mg dehydroepiandrosterone, 540 mg saw palmetto, 300 mg indole‐3‐carbinol, 625 mg chrysin, and 750 mg Tribulus terrestris per day)
Study: 7965657
Drug: 8-mg ondansetron
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-mg ondansetron tablet
Study: 7965657
Drug: 8-mg ondansetron
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-mg ondansetron tablet after a standard meal
Study: 7965657
Drug: 8-mg ondansetron
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-mg ondansetron tablet with magnesium hydroxide/aluminum hydroxide antacid
Study: 31900603
Drug: PF-06342674 (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06342674 (1, 3, 8 mg/kg/q2w or 6 mg/kg/q1w)
Study: 30641142
Drug: YH4808 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: YH4808 (100 mg)
Study: 30641142
Drug: YH4808 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: YH4808 (200 mg and 400 mg)